Expression and antimicrobial function of bactericidal permeability- increasing protein in cystic fibrosis patients

Infection and Immunity

Volumn 74, Issue 8, 2006, Pages 4708-4714

  Aichele, Diana ^a   Schnare, Markus ^a   Saake, Marc ^a   Röllinghoff, Martin ^a   Gessner, Andre ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AUTOANTIBODY; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; INTERLEUKIN 8; MEROPENEM; MESSENGER RNA; NEUTROPHIL CYTOPLASMIC ANTIBODY; PIPERACILLIN; TOBRAMYCIN;

AIRWAY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONICITY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG LAVAGE; NEUTROPHIL; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; STAINING;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NEUTROPHILS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM;

EID: 33746608909     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.02066-05     Document Type: Article

References (28)

1. Aebi, C., F. Theiler, C. C. Aebischer, and M. H. Schoeni. 2000. Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization. Pediatr. Infect. Dis. J. 19:207-212.
2. Calafat, J., H. Janssen, E. F. Knol, J. Malm, and A. Egesten. 2000. The bactericidal/permeability-increasing protein (BPI) is membrane-associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation. APMIS 108:201-208.
3. Canny, G., O. Levy, G. T. Furuta, S. Narravula-Alipati, R. B. Sisson, C. N. Serhan, and S. P. Colgan. 2002. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl. Acad. Sci. USA 99:3902-3907.
4. Carlsson, M., L. Eriksson, I. Erwander, J. Wieslander, and M. Segelmark. 2003. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies. Clin. Exp. Rheumatol. 21:895-100.
5. Ciofu, O., B. Riis, T. Pressler, H. E. Poulsen, and N. Hoiby. 2005. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 49:2276-2282.
6. Dorlochter, L., M. Carlsson, E. J. Olafsdottir, O. D. Roksund, K. Rosendahl, and G. Fluge. 2004. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. J. Cyst. Fibros. 3:179-183.
7. Eckert, M., I. Wittmann, M. Rollinghoff, A. Gessner, and M. Schnare. 2006. Endotoxin-induced expression of murine bactericidal permeability/ increasing protein is mediated exclusively by Toll/IL-1 receptor domain-containing adaptor inducing IFN-β-dependent pathways. J. Immunol. 176:522-528.
8. Elsbach, P. 1998. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J. Leukoc. Biol. 64:14-18.
9. Elsbach, P., and J. Weiss. 1998. Role of the bactericidal/permeability- increasing protein in host defence. Curr. Opin. Immunol. 10:45-49.
10. Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.
11. Hoiby, N. 2002. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J. Cyst. Fibros. 1:249-254.
12. Hoiby, N., H. Krogh Johansen, C. Moser, Z. Song, O. Ciofu, and A. Kharazmi. 2001. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 3:23-35.
13. Hubeau, C., M. Lorenzato, J. P. Couetil, D. Hubert, D. Dusser, E. Puchelle, and D. Gaillard. 2001. Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa. Clin. Exp. Immunol. 124:69-76.
14. Kettritz, R., J. C. Jennette, and R. J. Falk. 1997. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J. Am. Soc. Nephrol. 8:386-394.
15. Kobayashi, H. 2005. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Treat. Respir. Med. 4:241-253.
16. Krauss, R. D., and T. A. Rado. 1989. Current approaches to the molecular and physiological basis of cystic fibrosis. Am. J. Med. Sci. 298:334-341.
17. Little, R. G., D. N. Kelner, E. Lim, D. J. Burke, and P. J. Conlon. 1994. Functional domains of recombinant bactericidal/permeability increasing protein (rBPI23). J. Biol. Chem. 269:1865-1872.
18. Macia, M. D., D. Blanquer, B. Togores, J. Sauleda, J. L. Perez, and A. Oliver. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudamonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 49:3382-3386.
19. Oliver, A., R. Canton, P. Campo, F. Baquero, and J. Blazquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.
20. Rogan, M. P., C. C. Taggart, C. M. Greene, P. G. Murphy, S. J. O'Neill, and N. G. McElvaney. 2004. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J. Infect. Dis. 190:1245-1253.
21. Schultz, H., E. Csernok, A. Schuster, T. S. Schmitz, M. Ernst, and W. L. Gross. 2000. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI. Pediatr. Allergy Immunol. 11:64-70.
22. Schultz, H., S. Schinke, K. Mosler, K. Herlyn, A. Schuster, and W. L. Gross. 2004. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5α in vitro. Pediatr. Pulmonol. 37:158-164.
23. Schultz, H., J. Weiss, S. F. Carroll, and W. L. Gross. 2001. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies. J. Leukoc. Biol. 69:505-512.
24. Sediva, A., J. Bartunkova, J. Bartosova, C. Jennette, R. J. Falk, and H. S. Jethwa. 2003. Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa. Microbes Infect. 5:27-30.
25. Weiss, J., P. Elsbach, C. Shu, J. Castillo, L. Grinna, A. Horwitz, and G. Theofan. 1992. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J. Clin. Investig. 90:1122-1130.
26. Weiss, J., and I. Olsson. 1987. Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood 69:652-659.
27. Zarember, K., P. Elsbach, K. Shin-Kim, and J. Weiss. 1997. p15s (15-kD antimicrobial proteins) are stored in the secondary granules of rabbit granulocytes: implications for antibacterial synergy with the bactericidal/permeability-increasing protein in inflammatory fluids. Blood 89:672-679.
28. Zhao, M. H., D. R. Jayne, L. G. Ardiles, F. Culley, M. E. Hodson, and C. M. Lockwood. 1996. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM 89:259-265.